SCHEMBL1887405

SCHEMBL1887405

N#Cc1cnc(NCCc2cccc(F)c2)c(N(C=O)Cc2ccccn2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.51
RPS6KB1 P23443 1/20 0.38
AKT1 P31749 1/20 0.38
KMT2A Q03164 3/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
CCNC P24863 3/20 0.37
CDK8 P49336 3/20 0.37
CDKN1A P38936 1/20 0.37
CDK19 Q9BWU1 1/20 0.37
LMNA P02545 1/20 0.36
PKM P14618 1/20 0.36
GBA1 P04062 1/20 0.36
CSNK2A2 P19784 2/20 0.35
CSNK2A1 P68400 2/20 0.35
EGLN1 Q9GZT9 2/20 0.34
CXCR3 P49682 1/20 0.34
NPC1 O15118 1/20 0.34
RAB9A P51151 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1888574 0.88 KDM4E (0.53) KDM4ERPS6KB1AKT1KMT2AMAPT
SCHEMBL1629932 0.81 KDM4E (0.43) KDM4ERPS6KB1AKT1KMT2AMAPT
SCHEMBL1887474 0.80 KDM4E (0.48) KDM4EKMT2AMAPTMEN1L3MBTL1
SCHEMBL1630998 0.77 KDM4E (0.43) KDM4EKMT2AMAPTMEN1L3MBTL1
SCHEMBL12638980 0.77 KDM4E (0.53) KDM4ERPS6KB1AKT1KMT2AMAPT
SCHEMBL4179062 0.76 KDM4E (0.43) KDM4EKMT2AMAPTMEN1L3MBTL1
SCHEMBL1885720 0.75 KDM4E (0.39) KDM4ERPS6KB1AKT1KMT2AMEN1
SCHEMBL1631283 0.75 GBA1 (0.37) KDM4ERPS6KB1AKT1KMT2AMAPT
SCHEMBL1884307 0.75 GBA1 (0.46) KDM4ERPS6KB1AKT1KMT2AMAPT
SCHEMBL1631141 0.74 KDM4E (0.43) KDM4EKMT2AMAPTMEN1L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080132545-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-05 US claimed
US-7939548-B2 Aminopyridines, e.g.,N-{[6-(aminomethyl)(2-pyridyl)]methyl}(2-{[2-(3-fluorophenyl)ethyl]amino}-5-(3-pyridyl)(3-pyridyl))carboxamide; smooth muscle myosin or non-muscle myosin modulator; hypotensive agent; asthma, COPD, bronchoconstrictive disease, glaucoma, pre-menstrual cramps, erectile dysfunction CYTOKINETICS, INC. (US) 2011-05-10 US disclosed
US-20080132545-A1 Certain chemical entities, compositions, and methods CYTOKINETICS, INC. 2008-06-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080132545-A1 Certain chemical entities, compositions, and methods MYLK, MYH2, MYH10 KDM4E 3309/4885RPS6KB1 3506/4885AKT1 3467/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.